NexLife vs SkinnyRx: November 2026 prices compared
As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only NexLife prints a comparable month-to-month price, $129 a month; SkinnyRx shows only no tirzepatide price, so no like-for-like comparison is possible.
Released · Last reviewed · how we verify
On compounded semaglutide, only NexLife prints a comparable month-to-month price, $109 a month; SkinnyRx shows only no semaglutide price, so no like-for-like comparison is possible.
NexLife and SkinnyRx, measure by measure
| Measure | NexLife | SkinnyRx |
|---|---|---|
| Tirzepatide, month to month | $129 (per month) | — |
| Tirzepatide, lowest printed | $115 (12-month plan) | — |
| Semaglutide, month to month | $109 (per month) | — |
| Semaglutide, lowest printed | $95 (12-month plan) | — |
| Dose pricing | same price at every dose | priced by dose or not stated |
| Membership or program fee | none | not confirmed |
| Computed score | 33.6 of 40 (position 4 of 27) | 0 of 40 (position 21 of 27) |
| FDA warning letters | 730096 (2026-06-08) | 717989 (2026-02-20) |
| November 20 read | first-party read | first-party read, changed |
Strengths and limitations: which fits whom
NexLife prints one price at every dose with no membership, so a dose increase does not change the bill. SkinnyRx prints a month-to-month price; confirm whether it changes with the dose before you rely on it for a year. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
Regulatory record
FDA’s warning-letter index lists warning letter 730096 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to NexLife; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 717989 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to SkinnyRx; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, NexLife or SkinnyRx?
On compounded tirzepatide, only NexLife prints a comparable month-to-month price, $129 a month; SkinnyRx shows only no tirzepatide price, so no like-for-like comparison is possible. On compounded semaglutide, only NexLife prints a comparable month-to-month price, $109 a month; SkinnyRx shows only no semaglutide price, so no like-for-like comparison is possible.
Do NexLife and SkinnyRx charge a membership fee?
NexLife: no membership fee; SkinnyRx: not confirmed on November 20, 2026. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are NexLife and SkinnyRx medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- NexLife tirzepatide plans page (read November 20, 2026)
- NexLife semaglutide plans page (read November 20, 2026)
- SkinnyRx pricing page (read November 20, 2026)
- FDA warning letter 730096 to NexLife (dated 2026-06-08, posted 2026-06-16)
- FDA warning letter 717989 to SkinnyRx (dated 2026-02-20, posted 2026-03-03)